KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash & Current Investments (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Cash & Current Investments data on record, last reported at $3.7 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments fell 96.5% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $3.9 million, down 96.31%, while the annual FY2025 figure was $3.7 million, 96.5% down from the prior year.
  • Cash & Current Investments reached $3.7 million in Q4 2025 per EBS's latest filing, down from $249.2 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $642.6 million in Q4 2022 and bottomed at $200000.0 in Q2 2021.
  • Average Cash & Current Investments over 5 years is $234.4 million, with a median of $154.6 million recorded in 2024.
  • Peak YoY movement for Cash & Current Investments: crashed 99.93% in 2021, then soared 281.69% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $576.3 million in 2021, then grew by 11.5% to $642.6 million in 2022, then plummeted by 82.62% to $111.7 million in 2023, then decreased by 5.46% to $105.6 million in 2024, then tumbled by 96.5% to $3.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $3.7 million in Q4 2025, $249.2 million in Q3 2025, and $271.0 million in Q2 2025.